Investor Presentaiton
© Citadel Group | Investor Presentation | 12
о Statutory Financial performance
For personal use only
Statutory Revenue and EBITDA impacted by non-recurring abnormal
items
$m
Total Revenue
Gross Profit
Gross Profit Margin
EBITDA
EBITDA Margin
FY20
FY19
Change
122.1
99.2
23.1%
50.9
45.0
13.1%
41.7%
45.4%
16.8
23.3
(27.9%)
13.8%
23.5%
Depreciation & Amortisation
12.3
8.0
53.8%
EBIT
4.6
15.3
(69.9%)
Finance Costs
NPBT
Tax Expense
2.1
1.0
110.0%
Revenue $122.1 million
> Trading revenue from Enterprise, Health and Professional Services in line with
expectations - no material impact from COVID-19
> Technology revenues were impacted in Q4 from reduced university spend, offset by a
new contract win of $9.7m in May 2020 ($2.5m revenue recognised)
> Reversal of contract asset of $5.7m from FY17/FY18 impacted Professional Services
revenue, expected to be settled up to $5.0m in FY21
> Wellbeing trading results in line with expectations, revenue reduced by $0.6m as a
result of fair value adjustment to deferred revenue on Wellbeing acquisition
Gross margin of 41.7%
> Negatively impacted by revenue adjustments above, partially offset by accrued
expense reversal of $1.4m
2.5
14.3
(82.5%)
> No JobKeeper payments received in FY20
1.5
3.4
(55.9%)
NPAT from Continuing Operations
1.0
10.9
(90.8%)
EBITDA $16.8 million
> Abnormal expenses of $7.5m in respect of acquisition, integration and restructure
costs
> Full year impact of Gruden and Noventus, part year impact of Wellbeing acquisition
> Synergies program in Wellbeing will deliver savings of circa $1.5m in FY21
> Citadel restructure in February 2020 resulted in $2.1m annualised savings, a portion
of which will be reinvested back into the business to fund new growth strategiesView entire presentation